Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lifted its stake in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,500,000 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. Wave Life Sciences comprises about 2.5% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 11th biggest holding. Affinity Asset Advisors LLC’s holdings in Wave Life Sciences were worth $18,555,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in WVE. KBC Group NV acquired a new position in Wave Life Sciences in the fourth quarter worth approximately $67,000. Summit Investment Advisors Inc. raised its position in shares of Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares during the period. Westwood Wealth Management purchased a new stake in shares of Wave Life Sciences during the fourth quarter valued at $124,000. Raymond James Financial Inc. purchased a new stake in shares of Wave Life Sciences during the fourth quarter valued at $157,000. Finally, Victory Capital Management Inc. raised its holdings in Wave Life Sciences by 16.6% during the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock worth $180,000 after buying an additional 2,073 shares during the period. 89.73% of the stock is owned by institutional investors.

Wave Life Sciences Trading Up 6.2 %

NASDAQ:WVE opened at $6.00 on Tuesday. The firm has a market capitalization of $920.92 million, a PE ratio of -5.41 and a beta of -0.93. Wave Life Sciences Ltd. has a 1 year low of $4.25 and a 1 year high of $16.74. The firm’s fifty day simple moving average is $9.32 and its 200 day simple moving average is $11.66.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. As a group, analysts anticipate that Wave Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Analysts Set New Price Targets

WVE has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Wedbush started coverage on shares of Wave Life Sciences in a research report on Tuesday, April 8th. They issued an “outperform” rating and a $18.00 target price for the company. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Jefferies Financial Group assumed coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Wave Life Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $22.18.

Insider Transactions at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now owns 16,115 shares of the company’s stock, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.